High-Throughput 3-D Invasion Assay

Background:

The ability of cancer cells to invade into surrounding matrices is a critical determinant of metastasis and failure to prevent metastasis has reinforced the unmet need of targeting cancer invasion. To expedite the overall drug screening process, considerable efforts have been focused on development of practical 3D cell culture platforms for drug discovery. However, current 3D cell-based assays have not yet been incorporated into drug development programs that target metastatic process due to long incubation time requirement, lack standardization, or do not permit standardization for high- throughput screening.

Technology Overview:

Stony Brook University researchers have developed fluorine-containing asion in addition to being a inducer of apoptonext‐generation taxoid anticancer agents with superior pharmacological properties and improved potency against various classes of tumors, in particular drug‐resistant cancers and cancer stem cells. The potency of these next‐generation taxoids was evaluated against various drug‐sensitive and drug‐resistant cancer cell lines and patient‐derived cancer stem cells. The lead compound is a potent inhibitor of epithelial-mesenchymal transition(EMT), migration and invasion in breast cancer cells. Highly potent taxoids are also very important as the warheads of tumor‐targeting drug conjugates.  Further Details Zheng et al. Int J Oncolocy 2017 Mar; 50(3): 893-902

Advantages:

- Permits standardized high throughput drug screening - Effective and reproducible - Can be used with multiple cell types- Enables automated screening

Applications:

- Research - Drug Discovery

Intellectual Property Summary:

Patented,Patent application submitted

Stage of Development:

Issued Patent: 8,900,851 Pending Application

Licensing Status:

 

Licensing Potential:

 

Additional Information: